CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
0.9897
0.72%
Market Trading Hours* (UTC) Open now
Closes on Monday at 20:00

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.0131
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024901 %
Charges from full value of position ($-4.73)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.024901%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002679 %
Charges from full value of position ($0.51)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.002679%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 0.9969
Open 0.9969
1-Year Change 144.94%
Day's Range 0.9877 - 1.0169
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 4, 2024 0.9969 0.0399 4.17% 0.9570 1.0169 0.9570
Oct 3, 2024 0.9444 -0.0032 -0.34% 0.9476 0.9693 0.9369
Oct 2, 2024 0.9644 0.0275 2.94% 0.9369 0.9887 0.9169
Oct 1, 2024 0.9484 -0.0405 -4.10% 0.9889 0.9929 0.9378
Sep 30, 2024 0.9831 -0.0138 -1.38% 0.9969 1.0169 0.9569
Sep 27, 2024 1.0069 0.0200 2.03% 0.9869 1.0369 0.9869
Sep 26, 2024 0.9774 -0.0495 -4.82% 1.0269 1.0269 0.9670
Sep 25, 2024 1.0169 0.0300 3.04% 0.9869 1.0469 0.9818
Sep 24, 2024 0.9727 -0.0442 -4.35% 1.0169 1.0269 0.9328
Sep 23, 2024 1.0369 -0.0700 -6.32% 1.1069 1.1069 1.0369
Sep 20, 2024 1.1169 -0.0200 -1.76% 1.1369 1.1369 1.0869
Sep 19, 2024 1.1269 0.0000 0.00% 1.1269 1.1569 1.1169
Sep 18, 2024 1.1069 -0.0100 -0.90% 1.1169 1.1669 1.0969
Sep 17, 2024 1.1169 -0.0800 -6.68% 1.1969 1.1969 1.0969
Sep 16, 2024 1.1669 -0.0400 -3.31% 1.2069 1.2269 1.1569
Sep 13, 2024 1.1969 0.0000 0.00% 1.1969 1.2169 1.1769
Sep 12, 2024 1.1969 -0.0200 -1.64% 1.2169 1.2269 1.1869
Sep 11, 2024 1.2269 0.0100 0.82% 1.2169 1.2569 1.2069
Sep 10, 2024 1.2358 0.0400 3.35% 1.1958 1.2358 1.1858
Sep 9, 2024 1.2358 0.1000 8.80% 1.1358 1.2358 1.1358

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Ocugen, Inc. Company profile

Ocugen (OCGN) is a biopharmaceutical company focusing on discovering, developing, and commercialising gene therapies to cure blindness illnesses and creating a Covid-19 vaccine. 

Founded in 2006, Ocugen became a public company in 2014. The company’s shares are traded on the Nasdaq under the symbol OCGN.

Projects in the pipeline are Covid-19 vaccines, a Modifier Gene Therapy Platform and Novel Biologic Therapies for Retinal Diseases. 

For the Covid-19 vaccine, the company, in collaboration Bharat Biotech, was developing, manufacturing and commercialising COVAXIN for the prevention of the disease for US and Canada markets. COVAXIN is a whole-virion inactivated Covid-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus.

The Modifier Gene Therapy Platform is designed for retinal diseases, including retinitis pigmentosa (RP), leber congenital amaurosis (LCA) and dry age-related macular degeneration (AMD). The technology is licensed from the Schepens Eye Research Institute of Massachusetts Eye and Ear (Harvard Medical School).

The company is developing OCU200, a biologic product candidate for the treatment of severe vision-threatening diseases such as diabetic macular edema (DME), diabetic retinopathy (DR), and wet age-related macular degeneration (Wet-AMD). 

Patients affected by these diseases have common symptoms, such as blurry vision and increasing visual loss as the condition develops.

Another technology in the pipeline is OCU400, the company’s first product candidate developed with its Modifier Gene Therapy Platform.

Ocugen is headquartered in Malvern, Pennsylvania.

Industry: Biotechnology & Medical Research (NEC)

11 Great Valley Parkway
MALVERN
PENNSYLVANIA 19355
US

News

Gold's recent Story

Last week, we explored the key price drivers of gold, and how they impacted the price of the precious metal this year and last. Now, we’ll bring these factors to life in a chart, showing you ten instances the gold price responded to critical fundamental events, including central bank policies, global economic data, and geopolitical events.

15:36, 7 October 2024

September US Non-Farm Payrolls Preview

Kyle Rodda, Senior Market Analyst at Capital.com, previews the US Non-Farm Payrolls report for September. The article discusses market expectations of a stable labor market with 150,000 new jobs, an unchanged unemployment rate of 4.2%, and steady annual wage growth at 3.8%. It also highlights potential rate cuts by the Federal Reserve, revisions to past payroll data, and the reaction of various markets such as the US Dollar, S&P 500, and gold.

07:59, 2 October 2024

Market of the Month - Gold, an overview

In 2024, gold has been on an upward trajectory, hitting high after high as global markets face ongoing challenges. This precious metal, long seen as a safe haven, has been proving its worth, drawing attention from traders around the world as its bullish surge continues.

06:00, 30 September 2024

RBA Preview: Rates to remain unchanged with inflation-fighting still the focus

RBA Governor Michelle Bullock emphasizes inflation challenges for Australia's economy, citing supply shocks and demand-supply imbalances. Discover insights on CPI trends, interest rates, and the central bank's strategy for managing price pressures in 2024.

12:27, 20 September 2024

BoE Preview: no change expected but forward guidance will be key

The BoE is forecasted to leave rates unchanged in September as UK CPI remains stubborn.

14:53, 19 September 2024

FOMC Decision Review: A 50 point cut but the markets responded in a mixed fashion

Discover the US Federal Reserve’s latest 50 basis point cut and how the markets reacted. Stocks surged, the US Dollar fell, and the Fed hints at more aggressive cuts ahead.

11:30, 19 September 2024

Bank of Japan Preview

The Bank of Japan will meet on September 20, 2024, with markets anticipating minimal policy changes. However, inflation risks remain, with core CPI at 2.7% and potential for future interest rate hikes.

09:40, 17 September 2024

People also watch

BTC/USD

63,721.05 Price
+1.640% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

19,957.60 Price
-0.170% 1D Chg, %
Long position overnight fee -0.0249%
Short position overnight fee 0.0027%
Overnight fee time 21:00 (UTC)
Spread 1.8

Gold

2,647.92 Price
-0.230% 1D Chg, %
Long position overnight fee -0.0178%
Short position overnight fee 0.0096%
Overnight fee time 21:00 (UTC)
Spread 0.30

Oil - Crude

76.59 Price
+3.400% 1D Chg, %
Long position overnight fee 0.0139%
Short position overnight fee -0.0358%
Overnight fee time 21:00 (UTC)
Spread 0.030

Still looking for a broker you can trust?

Join the 650,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading